FGFR3 Fusion

CI-VAR-00001429Explore in graph →CIViC 5019

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Myeloproliferative Neoplasm1
ETV6::FGFR3 Fusion	Midostaurin	Predictive	D	Supports Sensitivity Response	3	submitted	EID10409 PKC412 inhibited the growth of TEL-FGFR3 fusion-transformed Ba/F3 cells by 25% at 100 nM, 45% at 200 nM, and 85% at nM in the absence of interleukin 3. The N540D mutation in the context of FGFR3 was i… (full text at CIViC) PMID 16091734 · Chen et al., 2005 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.